95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
SYSTEMATIC REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1565407
This article is part of the Research Topic Bispecific Antibodies and their Conjugates in Solid Tumors and Hematological Malignancies View all 3 articles
Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis
Provisionally accepted- 1 China Medical University, Shenyang, China
- 2 The First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, China
Background: Multiple myeloma (MM) is a hematological malignancy with limited treatment options for patients with relapsed/refractory MM (RRMM). Teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, has shown promising results in clinical trials and real-world studies.Methods: PubMed/MEDLINE, Web of Science, EMBASE, Cochrane Library, Clinical trial gov. and meeting libraries were searched from inception to November 14, 2024. Outcomes assessed included overall survival (OS), progression-free survival, time to next treatment, duration of response, overall response rate (ORR), ≥complete response (≥CR), ≥very good partial response (≥VGPR), VGPR, partial response and adverse events.Results: 34 studies involving 4,064 patients were included. In pairwise meta-analysis, teclistamab demonstrated superior OS (HR = 0.69, 95% confidence interval (CI): 0.54-0.89; p = 0.037) compared to existing RRMM treatments. Real-world studies showed comparable ORR (62%, 95% CI: 58-66%) but slightly lower survival outcomes, possibly because of shorter follow-up times and higher-risk populations. Subgroup analyses revealed enhanced efficacy with combination therapies (ORR: 85% vs 62%, p < 0.0001) and notable clinical benefits in the China cohort (≥VGPR: 77%, ≥CR: 58%). Safety profiles indicated manageable cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, though infection risks required vigilant management.Teclistamab continues to be a promising and effective treatment option for RRMM patients, including those previously exposed to BCMA-targeted therapies, and offers new hope for overcoming resistance and achieving better early disease control. Further research is needed to optimize its application in diverse populations, particularly in Asian cohorts.
Keywords: Teclistamab, Relapsed or refractory multiple myeloma, Meta-analysis, bispecific antibodies, Systematic reveiw
Received: 23 Jan 2025; Accepted: 28 Mar 2025.
Copyright: © 2025 Li, Zhao, Jiao, Dong, Wang and Yan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiaojing Yan, The First Affiliated Hospital of China Medical University, Shenyang, 110000, Liaoning Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.